Sox2 suppresses the invasiveness of breast cancer cells via a mechanism that is dependent on Twist1 and the status of Sox2 transcription activity by unknown
Wu et al. BMC Cancer 2013, 13:317
http://www.biomedcentral.com/1471-2407/13/317RESEARCH ARTICLE Open AccessSox2 suppresses the invasiveness of breast cancer
cells via a mechanism that is dependent on
Twist1 and the status of Sox2 transcription
activity
Fang Wu1†, Xiaoxia Ye1†, Peng Wang1, Karen Jung2, Chengsheng Wu1, Donna Douglas3, Norman Kneteman3,
Gilbert Bigras1, Yupo Ma4 and Raymond Lai1,2,5*Abstract
Background: Sox2, an embryonic stem cell marker, is aberrantly expressed in a subset of breast cancer (BC). While
the aberrant expression of Sox2 has been shown to significantly correlate with a number of clinicopathologic
parameters in BC, its biological significance in BC is incompletely understood.
Methods: In-vitro invasion assay was used to evaluate whether the expression of Sox2 is linked to the invasiveness
of MCF7 and ZR751 cells. Quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) and/or Western
blots were used to assess if Sox2 modulates the expression of factors known to regulate epithelial mesenchymal
transition (EMT), such as Twist1. Chromatin immunoprecipitation (ChIP) was used to assess the binding of Sox2 to
the promoter region of Twist1.
Results: We found that siRNA knockdown of Sox2 expression significantly increased the invasiveness of MCF7
and ZR751 cells. However, when MCF7 cells were separated into two distinct subsets based on their differential
responsiveness to the Sox2 reporter, the Sox2-mediated effects on invasiveness was observed only in ‘reporter
un-responsive’ cells (RU cells) but not ‘reporter responsive’ cells (RR cells). Correlating with these findings, siRNA
knockdown of Sox2 in RU cells, but not RR cells, dramatically increased the expression of Twist1. Accordingly, using
ChIP, we found evidence that Sox2 binds to the promoter region of Twist1 in RU cells only. Lastly, siRNA
knockdown of Twist1 largely abrogated the regulatory effect of Sox2 on the invasiveness in RU cells, suggesting
that the observed Sox2-mediated effects are Twist1-dependent.
Conclusion: Sox2 regulates the invasiveness of BC cells via a mechanism that is dependent on Twist1 and the
transcriptional status of Sox2. Our results have further highlighted a new level of biological complexity and
heterogeneity of BC cells that may carry significant clinical implications.
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Tumor invasiveness is a complex process in which malig-
nant cells dissociate and migrate from the primary site of
growth, which may eventually lead to the formation of
distant metastases [1]. In many types of solid tumor, it has
been shown that epithelial-mesenchymal transition (EMT)
is a crucial step for tumor invasiveness [2,3]. During EMT,
malignant epithelial cells shed their differentiated charac-
teristics (e.g. cell-cell adhesion, apical-basal polarity and
immobility) and acquire mesenchymal features (e.g. in-
creased motility and invasiveness) [4]. The induction of
EMT can be triggered by cytokines, such as TGF-β and
interleukin (IL)-8, as well as several transcriptional factors
including Twist1, Snail, and ZEB [5-9]. Twist1 has been
described to be one of the key promoters of EMT and in-
vasiveness in a number of cancer types [10-12]. In several
studies, Twist1 was found to be up-regulated by a number
of proteins including STAT3 [13], BMP2 [14], SRC-1 [15],
MSX2 [16], NF-κB [17], and ILK [18] and down-regulated
by miR-580 and CPEB1/2 [19]. In breast cancer (BC),
Twist1 has been found to promote EMT and invasiveness
[5]. A number of immunohistochemical studies have
described a significant positive correlation between Twist1
and the metastatic/invasive property of BC [5-8]. In an
animal model, siRNA knockdown of Twist1 was found to
inhibit BC cells to metastasize to the lungs [5]. Further-
more, the mechanisms by which Twist1 promotes tumor
invasiveness in BC have been extensively examined;
down-regulation of E-cadherin [9] and up-regulation of
SET8 [20], AKT2 [8], miRNA-10b [21], IL8 [22] and
PDGFα [23] have been implicated.
Sox2 (sex determining region Y-box protein 2) is a
transcription factor that plays a key role in maintaining
the pluripotency of embryonic stem cells [24-26]. The
importance of Sox2 in stem cell biology is highlighted by
the fact that Sox2 represents one of the 4 genes im-
plicated in the conversion of fibroblasts into inducible
pluripotent stem cells [27,28]. Recent studies have
shown that Sox2 is aberrantly expressed in several types
of solid tumors, including BC, lung cancer, prostate can-
cer, glioblastomas and melanomas [29-33]. The expres-
sion of Sox2 detectable by immunohistochemistry has
been found to positively correlate with the invasiveness
and metastatic potential of several types of solid tumors
[34-37]. Nevertheless, in-vitro studies that directly assess
the role of Sox2 in regulating tumor invasiveness are
relatively scarce [35-38]. In several types of cancer cells
(e.g., gliomas, melanomas and colorectal cancer), knock-
down of Sox2 using siRNA was found to decrease inva-
siveness [35-37]. In one study, enforced expression of
Sox2 in MCF7, an estrogen receptor-positive (ER+) BC
cell line, was found to increase invasiveness in an in-
vitro assay by approximately 60% [38]. The mechanisms
by which Sox2 regulates the invasiveness of BC cells arelargely unknown. For instance, whether the regulatory
effects of Sox2 on the invasiveness of BC are linked to
regulators of EMT (such as Twist1) has not been exam-
ined previously.
In this study, we aimed to further define the roles of
Sox2 in regulating the invasiveness of BC cells. In
contradiction with the conclusion of a recently published
paper [38], we found that Sox2 suppresses, rather than
increases, the invasiveness of MCF7 cells. Furthermore,
this biological effect is dependent on the regulation of
Twist1 expression by Sox2. When we assessed the roles
of Sox2 in the two distinct cell subsets of MCF7 sepa-
rated based on their differential responsiveness to the
Sox2 reporter, as shown previously [39], we found that
the Sox2-mediated effects on invasiveness in BC is re-
stricted to ‘reporter un-responsive’ (RU) cells. We be-
lieve that our results have shed important insights into
the biological significance of Sox2 in BC, the invasive-
ness property of BC, as well as a new level of biological
complexity of this type of cancer.
Methods
Cell culture
MCF7 and ZR751 were purchased from American Type
Culture Collection (ATCC, Rockville, MD). Both ZR751
andMCF7 cells weremaintained in high glucose Dulbecco's
Modified Eagle Medium (DMEM) (Life Technologies,
Grand Island, NY) supplemented with 10% fetal bovine
serum (FBS) (Sigma, Oakville, ON, Canada) and were
cultured under an atmosphere of 5%CO2 at 37°C.
Generation of stable cell lines
Stable cells expressing the Sox2 GFP reporter were gen-
erated as previously described [39]. Cells stably express-
ing the Sox2 GFP reporter were cultured in DMEM,
supplemented with 10% FBS, 100 U/ml penicillin, 100
ng/ml streptomycin. 1 μg/ml of puromycin was added to
the culture medium at all times. The generated stable
cell clones were analyzed for GFP expression by flow
cytometry every two weeks over a 4-month period. RR
and RU cells were sorted out based on GFP expression
and cultured separately. The two populations remained
98% pure over 4 months.
Gene silencing
MCF7 and ZR751 cells were transfected with 1 nmol of
SMARTpool siRNA designed against Sox2 (Thermo Scien-
tific). Scramble non-targeting siRNA (Thermo Scientific)
was used as the negative control. For all siRNA transfection,
a BTX 830 electroporation instrument (Harvard Apparatus,
Holliston, MA) was used. For double knockdown experi-
ments, SMARTpool siRNA designed against Twist1 from
Thermo Scientific was used.
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performed as previously described [39]. Briefly, pheonix
packaging cells were transfected with either pMXs Sox2
retroviral vector (Addgene, MA, USA) or empty vector
according to the manufacturer's suggestion. MCF7 cells
were infected with retroviral particles three times in 24
hour intervals. 48 hours after the final infection, cells
were overnight starved and were then used to perform
invasion assay.
Western blotting
Western blot analyses were performed as previously
described [40,41]. The following antibodies were used:
Sox2 (Cell Signaling Technologies), Twist1 (Santa Cruz),
γ-Tubulin (Sigma).
Cell viability
Cell viability was determined using the 3-(4,5-di-
methylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium, inner salt (MTS) assay
(Promega, Madison, WI) according to the manu-
facturer's protocol.
Cell invasion assay
As previously described, we assessed cell invasiveness
using the Cytoselect™ 24-well cell invasion assay kit (Cell
Biolabs, San Diego, CA, USA) according to the manufac-
ture’ s protocol [42]. Briefly, cells were overnight starved
prior to invasion assay. Approximately 1 × 105 cells in
serum free medium were plated in the top chamber and
medium supplemented with 10% FBS was used as a
chemo-attractant in the lower chamber. The cells were
then allowed to invade the reconstituted basement
membrane matrix for 24 hours. The invasive cells passed
the membrane were then dissociated from membrane,
lysed and quantified using CyQuant GR fluorescent Dye.
Quantitative RT-PCR
Total RNA was extracted using TRIzol according to the
manufacturer’s protocol. Quantitative RT-PCR was per-
formed using Applied Biosystem Prism 7900HT ins-
truments. The TaqMan gene expression assay (Applied
Biosystems) used were: Hs01548727_m1 (MMP2), Hs00
234579_m1 (MMP9), Hs01675818_s1 (Twist1), Hs0102
3894_m1 (E-cadherin), Hs00362037_m1 (N-cadherin,
Hs00232783_m1(ZEB1) and Hs00998133_m1 (TGF-β).
Primer sequences for Snail are: Forward 5'-acaaaggctg
acagactcactg-3′, Reward 5′-tgacagccattactcacagtcc-3′.
Primer sequences for Slug are: Forward 5′-gtctctcctgcac
aaacatgag-3′, Reverse 5′-atgctcttgcagctctctctct-3′. Pri-
mer sequences for MMP3: Forward 5′-cactcacagacc
tgactcggtt-3′, Reverse 5′- aagcaggatcacagttggctgg-3′.
Primer sequence for FAK are Forward 5′-gccttatgacg
aaatgctgggc-3′, Reverse 5′- cctgtcttctggactccatcct -3′.Human GAPDH was used as control. Expression of each
gene was measured in triplicate.
Chromatin immunoprecipitation (ChIP) assay
ChIP assay was performed as our previously described
[39]. The chromatin was extracted from MCF7-RR and -
RU cells. A normal rabbit IgG antibody and anti-Sox2
antibody (Santa Cruz) was then incubated with the chro-
matin. Isolated DNA was then amplified with Twist1
primers (−1478 to −1322 of transcriptional start site, 156
bp amplicons): Forward 5′-ggcgagtccgtactgagaag-3′ Re-
verse 5′- cgtttcaggtccatccctta-3′.
Statistical analysis
All the statistical analyses were performed using the
GraphPad Prism 5.1 program. Student T-test and One-
way ANOVA were used to calculate p value. Results are
presented as mean ± standard deviation.
Results
Sox2 suppresses the invasiveness of breast cancer cells
Using an in-vitro assay, we assessed if Sox2 regulates the in-
vasiveness of two ER + breast cancer cell lines (i.e., MCF7
and ZR751), both of which have shown the highest expres-
sion level of Sox2 described in our previous study [39]. As
shown in Figure 1A, siRNA knockdown of Sox2 resulted
in a significant increase in the invasiveness of MCF7 and
ZR751 cells. These changes were not due to a difference
in cell growth between cells treated with Sox2 siRNA or
scramble siRNA (Figure 1B). In contrast with the findings
of another group [38], we found no significant difference
in the invasiveness between MCF7 cells transfected with
an empty vector or a Sox2 expression vector (Figure 1C-D).
The suppression of invasiveness by Sox2 is dependent on
the status of the Sox2 transcription activity
As Sox2 is a transcription factor, we asked if Sox2 is
transcriptionally active in BC cells, and whether the status
of its activity has any impact on its effect on the invasive-
ness in BC.
To assess the Sox2 transcriptional activity, we have
employed a previously characterized Sox2 reporter. The
read-out of the reporter is provided by the inclusion of
green fluorescence protein (GFP), driven by a mCMV
promoter [39]. With the Sox2 reporter employed, we
had identified that MCF7 and ZR751 cells are composed
of two phenotypically distinct cell subsets that can be
separated based on their differential responsiveness to
the Sox2 reporter [39]. Specifically, cells showing Sox2
transcriptional activity are GFP-positive whereas those
showing no evidence of Sox2 transcriptional activity are
GFP-negative [39]. For the purpose of this study, the
former cell population is labeled ‘reporter responsive’ or
RR cells and the latter cell population is labeled ‘reporter
Figure 1 Sox2 suppresses invasiveness in breast cancer cells. (A) MCF7 and ZR751 cells were treated with Sox2 siRNA before subjecting to
invasion assay. siRNA knockdown of Sox2 significantly increased the invasiveness of MCF7 and ZR751cells. A scrambled siRNA sequence was used as a
control and results were normalized to the control. Triplicate experiments were performed. A representative experiment is shown (mean ± standard
deviation) (n = 3). Statistical significance was determined by Student's T-test. Western blots analysis showed that siRNA knockdown of Sox2 dramatically
decreased the expression of Sox2 in MCF7 and ZR751. (B) Cell viability was measured by the MTS assay. siRNA knockdown did not significantly change
the viability of MCF7 cells. Similar results were obtained from ZR751 cells. Triplicate experiments were performed (mean ± standard deviation) (n = 6).
Statistical significance was determined by Student's T-test. (C) Enforced expression of Sox2 did not significantly change the invasiveness of MCF7.
MCF7 cells transfected with empty vector were used as a control. Triplicate experiments were performed. A representative experiment is shown (mean
± standard deviation) (n = 3). (D) Cell viability was measured by the MTS assay. Enforced expression of Sox2 did not significantly change the viability of
MCF7 cells. Triplicate experiments were performed (mean ± standard deviation) (n = 6).
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generated stable cell clones expressing the Sox2 reporter
construct. RR and RU cells were further isolated by flow
cytometry and cultured separately. As shown in Additional
file 1: Figure S1, the RR and RU cells were readily identi-
fied using flow cytometry. Cells stably transfected with
the Sox2 reporter that have not been sorted into RR and
RU cells are labeled ‘Sox2R’. We have previously excluded
the possibility that the absence of GFP expression in RU
cells is due to a lack of Sox2 protein as the vast majority
of MCF7 and ZR751 cells expressed Sox2 detected by
flow cytometry. Furthermore, by subcellular fractionation,
we confirmed that Sox2 is present in the nuclei of these
cells [39].
When the invasiveness of RR cells, RU cells and the
unsorted Sox2R cells derived from MCF7 was compared,
no significant difference was observed among these
three cell populations (Figure 2A). However, as shown in
Figure 2B, siRNA knockdown of Sox2 resulted in a sig-
nificant increase in the invasiveness in MCF7-RU cells;
in contrast, no significant change was seen in MCF7-RRcells. This difference between the two cell subsets was
not due to a significant difference in their cell growth
(Figure 2C). In keeping with our previous observation
[39], siRNA knockdown of Sox2 also did not result in
any significant change in the viability of MCF7-RR and -
RU cell populations (Figure 2D). The similar experi-
ments were performed using ZR751-RU cells. In keeping
with the results of MCF7 cells, siRNA knockdown of
Sox2 in ZR751-RU cells significantly increased in the
invasiveness (Figure 2E).
Sox2 regulates Twist1 expression, but only in RU cells
To understand the mechanism by which Sox2 regulates
the invasiveness of the RU cells, we examined if Sox2
modulates the expression of factors known to play key
roles in regulating the invasiveness and/or EMT in vari-
ous types of cancers, including Snail1, Slug, ZEB1,
MMP2, MMP3, MMP9, Twist1, E-cadherin, N-cadherin,
FAK and TGF-β [43-47]. Using quantitative RT-PCR, we
found that siRNA knockdown of Sox2 in both MCF7-RR
and -RU cells did not result in significant changes in the
Figure 2 The suppressive effect of Sox2 on the invasiveness in RU subset but not RR subset. (A) Cell invasiveness was also assessed using
RR cells, RU cells and unsorted cells (labeled as 'Sox2R') derived from MCF7. No significant difference in invasiveness was observed between these three
cell populations. Triplicate experiments were performed. A representative experiment is shown (mean ± standard deviation) (n = 3). (B) MCF7-RR
and -RU cells were subjected to either scramble siRNA or Sox2 siRNA treatment for 24 hour before invasion assay. Sox2 siRNA treatment resulted in
significant increase in invasiveness in MCF7-RU cells; no significant change was observed in MCF7-RR cells. Triplicate experiments were performed. A
representative experiment is shown (mean ± standard deviation) (n = 3). (C) Cell viability of RR, RU, and unsorted cells (labeled as 'Sox2R) from MCF7
were assessed by the MTS assay. (D) MCF7-RR and -RU cells were treated with Sox2 siRNA or scramble siRNA before the MTS assay. No significant
change in cell viability was found after Sox2 siRNA treatment. (E) ZR751-RU cells were subjected to either scramble siRNA or Sox2 siRNA treatment for
24 hour before invasion assay. Sox2 siRNA treatment significantly increases the invasiveness in ZR751-RU cells. Cell viability assay was also performed
and no significant change was observed after Sox2 siRNA treatment.
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as MMP2, MMP3, MMP9, FAK and TGF-β (not shown).
As shown in Figure 3B and C, we found that siRNA
knockdown of Sox2 led to a significant up-regulation of
the Twist1 mRNA as well as an upregulation of the
Twist1 protein, although these changes were confined to
the RU cells. Correlating with these findings, the expres-sion level of E-cadherin, one of the key Twist1 down-
stream targets, was down-regulated in RU cells but not RR
cells (Figure 3B). N-cadherin, a cell-cell adhesion mediator,
was significantly up-regulated in MCF7-RU cells but not
-RR cells. Using ChIP assay, we were able to demonstrate
that Sox2 was bound to the promoter region of Twist1 in
RU cells but not RR cells (Figure 3D).
Figure 3 Modulation of Twist1 expression by Sox2 in RU cells but not RR cells. (A) By western blot analysis, the protein expression of Twist1
was examined in RR, RU and unsorted cells (labeled as 'Sox2R') from MCF7. MB231 was used as positive control. (B) MCF7-RR and -RU cells were
treated with either scramble siRNA or Sox2 siRNA. By quantitative RT-PCR, the expression level of a panel of EMT/invasiveness inducers were
examined, including Snail1, Slug, ZEB1, MMP2, MMP3, MMP9, Twist1, E-cadherin, N-cadherin, FAK and TGF-β. siRNA knockdown of Sox2 resulted in
significant up-regulation of Twist1 and N-cadherin, down-regulation of E-cadherin in MCF7-RU cells but not -RR cells. No significant change was
found in the expression level of Slug, Snail, and ZEB1, MMP2, MMP3, MMP9, FAK and TGF-β after siRNA knockdown of Sox2. Three representative
results (i.e., Slug, Snail, and ZEB1) were shown. Scramble siRNA was used as a control. (C) By western blot analysis, the protein expression level of
Twist1 was detected after siRNA knockdown of Sox2. (D) For the ChIP assay, a normal rabbit IgG antibody or a specific anti-Sox2 antibody was
incubated with cross-linked chromatin extracted from MCF7-RR and -RU cells. Isolated DNA was amplified with primer designed against the
proximal promoter of Twist1. Sox2 was found to bind to the gene promoter region of Twist1 only in RU but not RR cells. Input control that
represents DNA isolated from chromatin before immunoprecipitation shows equal loading. n.s represents no significant difference.
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via Twist1
We then asked if the Sox2-mediated modulation of inva-
siveness in RU cells is dependent on Twist1. As shown in
Figure 4, siRNA knockdown of Sox2 in MCF7-RU cells
led to a significant increase in invasiveness, whereas
siRNA knockdown of Twist1 led to a significant decreasein invasiveness. Importantly, simultaneous silencing of
Sox2 and Twist1 using siRNA largely abrogated the sup-
pressive effect of Sox2 on invasiveness in MCF7-RU cells.
These findings strongly suggest that Sox2 suppresses the
invasiveness property of RU cells via down-regulating
Twist1 in these cells. The same experiment was repeated
using MCF7-RR cells and we found no significant change
Figure 4 The role of Sox2 and Twist1 in RU cells. (A) MCF7-RU cells were subjected to either scramble siRNA, Sox2 siRNA, Twist1 siRNA
treatment, or both before cell invasion assay. siRNA knockdown of Sox2 in MCF7-RU cells significantly increased the invasiveness, whereas siRNA
knockdown of Twist1 resulted in a significant decrease in invasiveness; Simultaneous knockdown of Sox2 and Twist1 largely abrogated the
suppressive effect of Sox2 on invasiveness. Triplicate experiments were performed. A representative experiment is shown (mean ± standard
deviation) (n = 3). One-way ANOVA was used to calculated statistics. (B) By western blot analysis, Sox2 siRNA and Twist1 siRNA treatment
dramatically decreased the expression level of Sox2 and Twist1, respectively. (C) Cell viability was measured by the MTS assay. No significant
change was observed between the negative control and various treatments. (D) By quantitative RT-PCR, the expression level of E-cadherin was
measured. Cells treated with double scramble siRNA were used as a negative control and data is presented as percentages of control. Statistical
significance was determined by one-way ANOVA.
Wu et al. BMC Cancer 2013, 13:317 Page 7 of 11
http://www.biomedcentral.com/1471-2407/13/317in the invasiveness of these cells (Figure 5). Nevertheless,
siRNA knockdown of Twist1 resulted in a significant de-
crease in the invasiveness of MCF7-RR cells, suggesting
that Twist1, but not Sox2, is a key regulator of invasive-
ness in these cells. Again, the observed differences in inva-
siveness were not due to a significant difference in the cell
growth among the negative controls and various treatment
groups (Figure 5B).
Discussion
The aberrant expression of Sox2 in cancer cells has been
found to correlate with the invasiveness of several types
of solid tumors [30,34,35,37,48-50]. For instance, a high
level of Sox2 expression detectable by immunohisto-
chemistry was found to correlate with higher invasive-
ness and metastatic potential in gliomas and colorectal
cancer [35,36]. Furthermore, siRNA knockdown of Sox2
can result in decreased invasiveness in cell lines derivedfrom gliomas, melanomas and colorectal cancer [35-37].
However, it appears that Sox2 expression in cancer does
not always correlate with increased invasiveness and me-
tastasis. We found at least one previous study in which a
relatively low level of Sox2 expression in gastric cancer
correlates with increased invasiveness/metastatic poten-
tial [34]. In the current study, we also found evidence
that Sox2 suppresses invasiveness in BC. Thus, the bio-
logical effects of Sox2 in cancer cells are likely to be
tumor type-specific.
Our finding that Sox2 suppresses the invasiveness of
BC is in contrast with that made by another group, who
found that enforced expression of Sox2 in MCF7 cells
can increases their invasiveness by approximately 60%
[38]. In our study, we initially found that siRNA knock-
down of Sox2 significantly increased the invasiveness of
parental MCF7 cells and MCF7-RU cells. In view of the
discrepancy between our conclusion and that described
Figure 5 The role of Sox2 and Twist1 in RR cells. Similar experiments were performed in MCF7-RU cells as described in Figure 4. (A) siRNA
knockdown of Sox2 in MCF7-RR cells did not lead to a significant increase in invasiveness. Nevertheless, siRNA knockdown of Twist1 significantly
decreased the invasiveness. Cells treated with double scramble siRNA were used as a negative control. Triplicate experiments were performed. A
representative experiment is shown (mean ± standard deviation) (n = 3). One-way ANOVA was used to calculated statistics. (B) By western blot
analysis, Sox2 siRNA and Twist1 siRNA treatment dramatically decrease the expression level of Sox2 and Twist1, respectively. (C) Cell viability was
measured by the MTS assay. No significant change was observed between the negative control and various treatments.
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periment that examined the effects of enforced Sox2
over-expression in MCF7 cells, as described previously
[38], and we did not find any significant change in the
invasiveness of these cells (Figure 1C). We would like to
point out that the lack of response to enforced Sox2 ex-
pression in MCF7 is similar to the finding of one of pre-
vious studies, in which enforced expression of Sox2 in
MCF7 cells was found to result in no significant change
in mammosphere formation and cell growth [39]. While
we do not have definitive explanations for the discrep-
ancy between our results and the previously published
results [38], we have considered the possibility that the
MCF7 cell clones used in the two laboratories may be
different. We also have considered the possibility that
the in-vitro invasiveness assays between the two labora-
tories have different characteristics. Lastly, since the exact
Sox2 protein level has been shown to be functionally
important in ESCs [51,52], it is possible that the total
Sox2 protein levels after gene transfection are substantially
different between the two laboratories, and thus, leading
to substantially different biological responses.
The mechanisms by which Sox2 regulate tumor inva-
siveness have not been extensively studied. In the litera-
ture, we were able to identify only 3 studies that are
directly relevant to this subject. In all of these threestudies (using cell lines derived from colorectal cancer,
melanomas and gliomas, respectively), siRNA knock-
down of Sox2 was found to decrease invasiveness; in the
same three studies, the decrease in invasiveness was
found to correlate with a decreased expression level of
one of the following molecules: MMP2, MMP3 or FAK
[36,37,53]. To our knowledge, the mechanisms by which
Sox2 regulates invasiveness in BC are not known. Thus,
we screened a panel of factors known to play roles in
regulating cell invasiveness/EMT in various types of can-
cer. In contrast with the previous reports, we did not
find any appreciable changes in the expression levels of
MMP3, MMP2 and FAK. Instead, we identified Twist1
as the only protein that is regulated by Sox2 in RU cells.
Twist1 has been reported to be one of the master reg-
ulators of invasiveness and EMT, and dysregulation of
Twist1 expression and function has been implicated to
be associated with cancer progression [54-56]. In BC, a
high level of Twist1 expression is more common in inva-
sive lobular carcinomas [5]. While siRNA knockdown of
Twist1 in BC cells led to a decrease in invasiveness [57],
enforced expression of Twist1 in BC cells converts its
normal epithelial cell morphology to a spindle-like/fibro-
blastic morphology [5,58]. In keeping with the concept
that Twist1 plays a key role in regulating invasiveness in
BC, siRNA knockdown of Twist1 decreased the invasive-
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30% (Figures 4A and 5A).
As mentioned in the introduction, the expression of
Twist1 has been shown to be regulated by a number of
proteins such as STAT3, BMP2 and SRC-1. The expres-
sion of Sox2 has been shown to correlate with that of
Twist1 in human glioblastoma cells [59], although direct
proof that Sox2 regulates the expression of Twist1 is
lacking. For the first time, we have provided direct evi-
dence that the expression of Twist1 in BC is regulated
by Sox2, and this regulation only occurs in the RU cells.
Results from our ChIP studies further support the fact
that Twist1 is regulated by Sox2 only in RU cells. Al-
though Sox2 does not respond to the reporter in RU
cells, possibly due to the fact that Sox2 in RU cells can-
not bind to the Sox2 binding motif present in the Sox2
reporter [39], Sox2 in RU cells can bind to the alterna-
tive Sox2 binding motif present in the Twist1 gene
promoter and thus suppress its expression as well as in-
vasiveness. These findings are in parallel to the findings
that Sox2 is known to negatively regulate a set of genes
in ESCs. In contrast, in RR cells, Sox2 does not bind to
the promoter region of Twist1 and the expression of
Twist1 is regulated by other factors. The mechanism
underlying the decision as to whether Sox2 binds to the
Twist1 gene promoter is under active investigation in
our laboratory. Since the transcription activity of Sox2 in
normal ESCs has been shown to be modulated by its
binding partners, we speculated that a similar scenario
may occur in BC cells. Taken together, our findings sug-
gest that the Sox2 transcriptional activity and Twist1
can serve as markers to predict invasiveness in breast
cancer cells.
An important concept emerged from the results of this
study is related to the significance of the dichotomy of
BC cells separated based on the differential responsive-
ness to the Sox2 reporter. Specifically, based on our
double siRNA knockdown experiments (Figure 4), the
Sox2-Twist1 axis plays a key role in regulating the inva-
siveness in RU cells. In contrast, Twist1, but not Sox2,
plays a key role in regulating the invasiveness of RR
cells. While the true biological significance of these ob-
servations requires further studies, we believe that our
results have highlighted a new level of biological com-
plexity of BC. In view of this new knowledge, one may
wonder if our current treatments of BC, which are
designed based on the assumption that BC cells within a
tumor are composed of a biologically uniform popula-
tion of cancer cells, are fundamentally inadequate. This
newly discovered biological complexity of BC cells may
prompt us to consider treatment strategies that are
based on the recognition of phenotypically distinct cell
subsets in BC that are driven by different biochemical
pathways.Conclusion
In summary, we reported for the first time that Sox2
suppresses invasiveness in BC cells, but only in RU sub-
set. Moreover, Sox2 was found to be a major regulator
of Twist1 by controlling the expression level of Twist1.
Results from our studies have further supported that the
dichotomy of BC based in their differential responsive-
ness to the Sox2 reporter carries biological importance,
highlighting a new level of biological complexity of BC.
Additional file
Additional file 1: Figure S1. Identification of the dichotomy of BC cells
based on the differential responsivenss to the Sox2 reporter. (A) MCF7
was stably transfected with either the Sox2 GFP reporter or mCMV lentiviral
vector. Cells stably transfected with the Sox2 GFP reporter were labeled as
'MCF7 Sox2R'. Cells stably transfected with mCMV control were labeled as
'MCF7 mCMV'. GFP expression was measured by flow cytometry. Cells
showing Sox2 transcriptional activity are GFP-positive whereas those
showing no evidence of Sox2 transcriptional activity are GFP-negative. For
the purpose of this study, the former cell population is labeled ‘reporter
responsive’ or RR cells and the latter cell population is labeled ‘reporter
un-responsive’ or RU cells. (B) To further examine the biology of these two
cell subsets, we isolated and cultured the GFP-positive (labeled as 'RR') and
GFP-negative cells (labeled as 'RU') separately from MCF7 cells.
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